Systematic collection and consistency of the unified database from the Pulmonary Oncology Translational Group (GTOP)

• Grant number: 22/00479-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: June 01, 2022
• End date: May 31, 2024
• Field of knowledge: Interdisciplinary Subjects
• Principal Investigator: Letícia Ferro Leal
• Grantee: Alice Ornellas Ferrari
• Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil

Abstract

Lung cancer is marked by worrying epidemiological data, such as high incidence, low survival, and late diagnosis. At the Hospital de Amor (HA), 540 cases were diagnosed in 2019, 70% with metastatic disease. Studies involving the collection of consistent and secure data are relevant to improving the clinical status of patients. For this reason, the Translational Group on Pulmonary Oncology (GTOP) aims to unify data from patients treated at HA in a single database on the REDCap platform to generate consistent data on the profile of patients and facilitate other research projects in different areas. Objectives: to carry out a survey of sociodemographic, clinical, pathological, and molecular data of patients with lung cancer and improve the GTOP database. Methodology: the information contained in the electronic and physical records of 2000 HA patients will be collected and included in the GTOP database stored in the REDCap platform. Forms containing variables common to all potential projects will be filled out ("general information", "pathology", "clinical data and treatment", "molecular diagnosis" and "follow up"). After the data collection is completed, the database consistency will be carried out - through "data quality" and manual curation. At the end, descriptive statistics of all cases will be performed. Expected results: for a sample of 2,000 patients, an average age of around 60 years is expected, with most patients being male. About 80% of patients who are active smokers or ex-smokers are expected, most cases present stage IV at diagnosis, and about 20% of all cases with curative intent treatment. It is estimated that about 20% of patients with mutations in the EGFR gene and those diagnosed from 2011 onwards have been treated with TKi.(AU)